Breaking News

Marken Releases Results of Logistics Survey

April 3, 2014

Nature and complexity of drug candidates drives increase in use of dedicated supply chain providers

Marken has released the results of an independent market research study on market trends, challenges, and selection criteria for logistics providers in the pharma industry. The survey, conducted by an outside firm, included 250 decision makers of clinical trial logistics services from pharma companies, central labs, CROs, and manufacturing service providers in North America, Central & South America, Europe, and Asia.
According to the report, 64% of supply chain executives plan to increase their clinical trial logistics spend in the next two years. Respondents cited that the nature and complexity of new drugs and their protocols entering clinical development will increase their use of dedicated supply chain providers in the space.
The main reasons for the use of specialty providers include temperature control capabilities (57%) and guaranteed on time delivery within specifications (53%), as well as real time traceability of shipments (49%). Also, more than 50% reported that their company had moved their clinical trials logistics business to a dedicated supply chain provider within the previous 24 months.
Wes Wheeler, chief executive officer of Marken, said, "An increasing focus on rare diseases requires the industry to recruit patients from a larger pool of countries across the globe. The increased complexity of the drugs themselves, many of which are temperature sensitive and of high value, tells us the service provided by a specialty courier such as Marken satisfies a critical need in the supply chain and the successful completion of each clinical trial. We were very pleased to reaffirm that our strategy aligns well with what our clients and potential clients need most."

Related Packaging:

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.